These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1917463)

  • 1. [Systemic treatment of common warts with beta-interferon].
    Schöfer H; Sollberg S
    Hautarzt; 1991 Jun; 42(6):396-8. PubMed ID: 1917463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon.
    Montalto G; Tripi S; Cartabellotta A; Fulco M; Soresi M; Di Gaetano G; Carroccio A; Levrero M
    Am J Gastroenterol; 1998 Jun; 93(6):950-3. PubMed ID: 9647026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of recurrent common warts with one low dose of intralesional natural human leukocyte interferon alpha.
    Pueyo S; Criscuolo M; Davidovich C; Zorzópulos J; Pesce A; Díaz A
    J Biol Regul Homeost Agents; 1990; 4(2):47-50. PubMed ID: 2260502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial.
    Musch E; Andus T; Malek M; Chrissafidou A; Schulz M
    Z Gastroenterol; 2007 Dec; 45(12):1235-40. PubMed ID: 18080224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential phase II trials of fluorouracil and interferon beta ser with or without sargramostim in patients with advanced colorectal carcinoma.
    Wadler S; Haynes H; Rozenblit A; Hu X; Kaleya R; Wiernik PH
    Cancer J Sci Am; 1998; 4(5):331-7. PubMed ID: 9815298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular beta-interferon treatment for severe vulvar vestibulitis.
    Bornstein J; Pascal B; Abramovici H
    J Reprod Med; 1993 Feb; 38(2):117-20. PubMed ID: 8383204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
    Durelli L
    J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
    Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
    Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C.
    Kaito M; Yasui-Kawamura N; Iwasa M; Kobayashi Y; Nakagawa N; Fujita N; Ikoma J; Gabazza EC; Watanabe S; Adachi Y
    Hepatogastroenterology; 2003; 50(51):775-8. PubMed ID: 12828083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
    Hernandez-Perez MA;
    Rev Neurol; 2009 May 16-31; 48(10):505-8. PubMed ID: 19434583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cimetidine treatment for viral warts enhances IL-2 and IFN-gamma expression but not IL-18 expression in lesional skin.
    Mitsuishi T; Iida K; Kawana S
    Eur J Dermatol; 2003; 13(5):445-8. PubMed ID: 14693487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of periungual warts using photodynamic therapy: a pilot study.
    Schroeter CA; Kaas L; Waterval JJ; Bos PM; Neumann HA
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1170-4. PubMed ID: 17894700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warts of the nail unit: surgical and nonsurgical approaches.
    Tosti A; Piraccini BM
    Dermatol Surg; 2001 Mar; 27(3):235-9. PubMed ID: 11277888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.